Skip to main content
. 2023 Jun 18;9(6):e17427. doi: 10.1016/j.heliyon.2023.e17427

Table 3.

Serum levels of IL-23 and IL-27 in relation to the clinical characteristics of RRMS patients.

Variables Groups Mean ± SD or Median [IQR] p-value
IL-23 (pg./ml)
Gender Female (n = 57) 178.8 ± 93.8 0.342
Male (n = 10) 209.2 ± 86.5
Age at disease onset(a <28 years (n = 33) 192.7 ± 80.2 0.421
≥28 years (n = 34) 174.3 ± 103.8
Duration of disease (b ≤10 years (n = 34) 183.6 ± 110.5 0.979
>10 years (n = 33) 183.1 ± 71.7
EDSS (c ≤2 (n = 38) 172.3 ± 100.8 0.257
>2 (n = 29) 197.7 ± 80.4
Number of relapses under treatment (d <2 (n = 42) 186.0 ± 95.0 0.763
≥2 (n = 25) 178.9 ± 90.5
Duration of Disease-modifying treatment (e <72 months 194.2 ± 102.7 0.404
≥72 months 175.1 ± 84.8
Disease-modifying treatment Interferon-beta (n = 33) 183.3 ± 108.8 0.996
Glatiramer acetate (n = 34) 183.4 ± 75.6
IL-27(pg./ml)
Gender Female (n = 57) 19.9 ± 4.9 0.139
Male (n = 10) 22.5 ± 5.2
Age at disease onset (a <28 years (n = 33) 21.7 ± 5.3 0.026*
≥28 years (n = 34) 19.0 ± 4.4
Duration of disease (b ≤10 years (n = 34) 19.9 ± 3.9 0.554
>10 years (n = 33) 20.6 ± 5.6
EDSS (c ≤2 (n = 38) 20.1 [16.6; 23.8] 0.672
>2 (n = 29) 19.2 [16.5; 22.5]
Number of relapses under treatment (d <2 (n = 42) 20.2 ± 5.0 0.764
≥2 (n = 25) 20.6 ± 4.9
Duration of disease-modifying treatment (e <72 months 20.3 ± 4.5 0.922
≥72 months 20.4 ± 5.3
Disease-modifying treatment Interferon-beta (n = 33) 21.4 ± 5.4
Glatiramer acetate (n = 34) 19.3 ± 4.4 0.079

IQR = [Q1, Q3] where Q1 = Quartile1; Q3 = Quartile 3; n = number of cases; p-values were obtained from Student-t test with equal variances or Welch Two Sample t-test; (a the median value was equal to 28 years; (b the median value was equal to 10 years;(c the median value was 2 points; (d the median value was equal to one relapse; (e the median value was equal to 72 months; *significant result: p < 0.05.